Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred
Journal of Psychopharmacology November 16, 2023 DOI: 10.1177/02698811231200019 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Sample size | 93 |
| Population | Clinical trials on classical psychedelics |
| Topics | Ayahuasca LSD Psilocybin |
| Keywords | Hallucinogen Clinical psychology Parapsychology Population Rating scale Level of consciousness Psychotherapist |
| Citations | 31 |
| Key findings | Seventeen different rating scales were used across 93 trials of classical psychedelics, with the five most utilized being the Five-Dimensional Altered States of Consciousness Questionnaire, visual analog or Likert scales, the Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Abnormer Psychischer Zustand. |
Abstract
Background: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of consciousness, characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning. It is important to have reliable instruments for quantifying these altered states in trials, due to a plausible link between the acute subjective experience and treatment outcome.
Methods: We conducted a review of outcome measures applied in research on classical psychedelics to assess one or more dimensions of the acute subjective psychedelic experience. Three relevant databases were searched electronically. Two reviewers independently conducted article selection and data extraction regarding the instruments, dimensions, geography, population, and psychedelic substance investigated in the included studies. We identified the five most utilized instruments for the most recent 6 years, as well as the five most utilized instruments for each psychedelic.
Results: We included 93 papers, which reported on 93 unique trials and utilized 17 different rating scales. Of these, the most utilized were the Five-Dimensional Altered States of Consciousness Questionnaire, visual analog or Likert scales specially developed for the trials, the Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Abnormer Psychischer Zustand.
Discussion: Considerable variability was found in the instruments utilized in clinical trials on classical psychedelics. We advise and encourage the development of a core outcome set for psychedelic research to enable altered state comparisons across compounds, participants, and settings. We further advise that instruments be designed to assess the “setting” of a psychedelic experience.
Comparable studies
Other narrative reviews on ayahuasca, most cited first.
Citations in the library
Cited by 30
- The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews May 1, 2025
- Wolves Among Sheep: Sexual Violations in Psychedelic-Assisted Therapy. The American Journal of Bioethics January 13, 2025
- Psychedelic risks and benefits: A cross-sectional survey study. Journal of Psychopharmacology May 1, 2025
- Psychedelics and the treatment of eating disorders: considerations for future research and practice. Journal of Eating Disorders October 22, 2024
- Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire Journal of Psychopharmacology August 13, 2024
and 25 more in the library
Cites 49
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 44 more in the library